Ambulatory CPAP Titration in Moderate Obstructive Sleep Apnea (ATMOS)

November 19, 2020 updated by: Universitaire Ziekenhuizen KU Leuven

The aim of this trial is to compare two different ways of CPAP titration:

CAP titration with fixed pressure vs. auto-titrating CPAP.

Study Overview

Status

Unknown

Intervention / Treatment

Detailed Description

Continuous positive airway pressure (CPAP) for the treatment of moderate obstructive sleep apnea (OSA) is only reimbursed in Belgium after in-laboratory overnight titration. Nevertheless, in a recent clinical practice guideline of the AASM, it is recommended that PAP therapy can be initiated using either in-laboratory titration or auto-titrating CPAP (APAP) at home in OSA patients without significant comorbidities. Indeed, several studies evaluated the impact of titration with APAP at home in these patients and showed that the outcome is comparable with in-hospital titration. Up to now, evidence for home titration with fixed CPAP (and follow-up via telemonitoring) is very limited. The use of sleep laboratory space is costly and limits access for diagnostic studies. This study aims to evaluate whether CPAP titration at home with fixed CPAP produces outcomes equal to those following APAP titration.

Study Type

Interventional

Enrollment (Anticipated)

264

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Leuven, Belgium, 3000
        • Recruiting
        • UZ Leuven
        • Contact:
          • Dries Testelmans, MD, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • moderate OSA (obstructive AHI 15-30/u on initial PSG)

Exclusion Criteria:

  • Presence of hypoventilation
  • Presence of central sleep apnea (central AHI ≥ 15)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Fixed CPAP titration at home

Patients will start CPAP treatment with a pressure that is calculated by the following formula (predicted pressure = (0.13 x BMI) + (0.16x neck circumference in cm) + (0.04 x AHI)) with a maximal pressure of 10 cmH2O. After 3 nights and after 7 nights, CPAP data will be remotely evaluated and pressure will be adapted based on the following rules:

  • After 3 nights: median obstructive AHI<5/h: decrease pressure with 2 cmH2O; median obstructive AHI>5/h: increase with 2cmH2O
  • After 7 nights: median obstructive AHI>5/h of 4 nights after last adaptation: increase with 2 cmH2O
Fixed CPAP or APAP titration at home
ACTIVE_COMPARATOR: APAP titration at home
Patients will start CPAP treatment with an auto-adjusting CPAP device with pressure levels between 4 and 12 cmH2O. After 7 nights of titration, the optimal pressure will be determined by analyzing the median of the nightly pressure that included 95% of the periods (percentile 95). CPAP treatment will be continued with this fixed optimal pressure.
Fixed CPAP or APAP titration at home

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
CPAP adherence
Time Frame: 3 months
Usage of the device (mean number of hours/day)
3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Effective pressure level
Time Frame: 2 weeks
Optimal pressure of CPAP therapy
2 weeks
Residual apnea/hypopnea index
Time Frame: 2 weeks
Residual respiratory events during treatment with optimal CPAP pressure during PSG
2 weeks
Mask leaks
Time Frame: 2 weeks
Objective leaks (L/min) during CPAP treatment
2 weeks
Proportion of good titration
Time Frame: 2 weeks
Number of patients with residual AHI < 10 (objectivated with PSG)
2 weeks
Residual device AHI
Time Frame: 3 months
Residual AHI as determined from device data
3 months
Epworth Sleepiness Scale
Time Frame: 3 months
Daytime sleepiness (range: 0-24 - higher score means worse outcome)
3 months
Blood pressure
Time Frame: 3 months
Blood pressure measurement
3 months
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: 3 months
Sleep quality (range: 0-21 - higher score means worse outcome)
3 months
36-Item Short Form Health Survey
Time Frame: 3 months
Quality of life (range: 0-100 - higher score means better outcome)
3 months
Hospital contacts
Time Frame: 3 months
Number of contacts with the hospital
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Dries Testelmans, MD, PhD, UZ Leuven

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

October 14, 2019

Primary Completion (ANTICIPATED)

October 1, 2021

Study Completion (ANTICIPATED)

December 31, 2021

Study Registration Dates

First Submitted

October 14, 2019

First Submitted That Met QC Criteria

October 14, 2019

First Posted (ACTUAL)

October 16, 2019

Study Record Updates

Last Update Posted (ACTUAL)

November 23, 2020

Last Update Submitted That Met QC Criteria

November 19, 2020

Last Verified

November 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sleep Apnea, Obstructive

Clinical Trials on PAP titration at home

3
Subscribe